Compare OPAL & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | MNOV |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 66.9M |
| IPO Year | 2021 | 2004 |
| Metric | OPAL | MNOV |
|---|---|---|
| Price | $2.51 | $1.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.91 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 272.4K | 54.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $348,975,000.00 | $2,360,807.00 |
| Revenue This Year | $17.60 | N/A |
| Revenue Next Year | $8.78 | N/A |
| P/E Ratio | $15.93 | ★ N/A |
| Revenue Growth | 16.34 | ★ 194.15 |
| 52 Week Low | $1.26 | $1.17 |
| 52 Week High | $4.08 | $1.96 |
| Indicator | OPAL | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 58.86 | 46.83 |
| Support Level | $2.08 | $1.21 |
| Resistance Level | $2.54 | $1.43 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 66.38 | 19.34 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.